The home sleep testing industry is approaching one of its most significant reimbursement transitions in years. Beginning Jan. 1, 2027, changes to the Current Procedural Terminology (CPT) coding structure for unattended sleep studies are expected to reshape how providers document, bill, and receive reimbursement for HST services. For sleep physicians, diagnostic testing organizations, and health care administrators, understanding these changes will be essential to maintaining financial stability, operational efficiency, and patient access to care.
As chief operating officer and executive vice president of iSleep Physicians, I have witnessed firsthand how rapidly HST has evolved. What was once a relatively straightforward diagnostic service has become an increasingly sophisticated component of sleep medicine, incorporating advanced technology, remote patient engagement, comprehensive data analysis, and specialized physician interpretation.
While the upcoming reimbursement changes represent an effort to modernize a coding framework that has struggled to keep pace with these advancements, they also raise important questions about whether the new reimbursement framework will adequately reflect the true cost and clinical complexity of delivering quality sleep diagnostic services. For many providers, the central question has shifted from what the new rates will be to whether those rates will be sufficient to sustain quality services and financially viable operations.
Understanding the New Reimbursement Structure
In July 2026, CMS released its proposed Calendar Year 2027 Medicare Physician Fee Schedule, outlining significant changes to unattended sleep testing reimbursement. The proposal addresses six new CPT codes intended to replace existing codes 95800, 95801, and 95806.1 The new structure separates technical services from professional interpretation and categorizes studies according to complexity. As of Nov. 6, 2026, these codes have now been finalized.2
Three new codes, identified as 95843 through 95846, address the technical components of unattended sleep studies, including equipment setup, data acquisition, and technical analysis. Three additional codes, 95847 through 95849, address physician or other qualified health care professional interpretation and reporting. The classifications distinguish low-, moderate-, and high-complexity studies based on recording channels and physiologic parameter categories.2
This represents a meaningful departure from the existing framework. Rather than relying primarily on traditional testing configurations, the new structure attempts to recognize differences in diagnostic technology and the complexity of services being delivered. It also introduces an important operational distinction: Providers will need to account for technical and professional services separately rather than relying on the familiar global coding structure.
Although this modernization is a welcome development, the finalized reimbursement valuations continue to raise concerns throughout the industry.
Financial and Clinical Implications for Providers
One of the most pressing concerns surrounding the changes is whether the reimbursement methodology adequately accounts for the operational resources required to deliver modern HST services. Industry stakeholders have raised concerns that the proposed technical and professional reimbursement valuations may not fully recognize the resources necessary to operate modern HST programs.
This concern reflects a broader reality within our industry. Delivering a successful home sleep study involves far more than placing a diagnostic device in a patient’s hands. It requires patient education, equipment preparation, shipping and logistics, technical troubleshooting, data validation, quality assurance, cybersecurity, and clinical coordination. These services are essential to obtaining reliable diagnostic information, yet many remain largely invisible when reimbursement is evaluated solely through the lens of the completed test.
The CMS proposal offered insight into how these operational expenses would be evaluated. CMS has questioned several assumptions underlying the proposed technical component valuations, including clinical labor time, equipment utilization, and the adequacy of equipment pricing documentation. For example, the proposed pre-service clinical labor allocation increases from 15 minutes for lower-complexity studies to 25 minutes for high-complexity studies, while post-service labor allocations range from 40 to 70 minutes. CMS has also questioned whether an assumed 16 hours of equipment utilization accurately reflects typical testing practices.3
These details matter because the technical component represents a substantial portion of the cost of delivering HST services. Changes to the underlying practice expense assumptions could materially influence final reimbursement.
Based on my experience overseeing sleep medicine operations under the previous reimbursement framework, Medicare reimbursement for HST services ranged from approximately $125 to $187, with an estimated blended rate of roughly $156. The updated 2027 reimbursement figures provide a more specific basis for planning, replacing earlier projections with payments that vary by study complexity. The financial impact on individual providers will depend on their mix of low-, moderate-, and high-complexity studies, making it essential to evaluate reimbursement alongside testing costs and clinical needs.
A closer examination of the updated 2027 Medicare Physician Fee Schedule rates shows combined national average technical and professional payments of $83.53 for low-complexity studies, $125.95 for moderate-complexity studies, and $217.63 for high-complexity studies, before geographic adjustments. These totals comprise technical payments of $46.01, $74.72, and $145.52, respectively, plus professional interpretation payments of $37.52, $51.23, and $72.11. These differences underscore the importance of aligning operational planning and device capabilities with the level of testing clinically appropriate for each patient.
Based on my review of the CMS reimbursement table and its channel and parameter requirements, it appears that most current Type 3 HST devices will fall within the moderate-complexity category, most Type 2 devices within the high-complexity category, and most Type 4 devices within the low-complexity category. However, classification will depend on whether the study meets the specific requirements of the applicable code, rather than its traditional device type alone.
The substantially greater high-complexity estimate reflects a different category of diagnostic service rather than an across-the-board reimbursement increase. The financial impact will therefore depend heavily on each organization’s testing mix, equipment capabilities, payer contracts, and allocation of technical vs. professional services.
For organizations operating on narrow margins, a reduction of this magnitude could significantly affect staffing decisions, technology investments, and long-term sustainability. Smaller diagnostic organizations and providers serving rural communities could be particularly vulnerable, especially when they lack the patient volumes necessary to offset declining reimbursement through economies of scale.
Equally important is the potential impact on physician interpretation. As diagnostic technologies advance, physicians are increasingly responsible for evaluating complex physiologic information, determining study adequacy, identifying sleep-disordered breathing, and integrating findings into individualized treatment recommendations. These responsibilities extend well beyond reviewing automated results.
Under the new rule, CMS assigns physician work relative value units (RVUs) of 0.81, 1.05, and 1.50 to the low-, moderate-, and high-complexity professional interpretation codes, respectively. Notably, CMS decided to increase its proposed work RVU of 1.42 up to 1.50 for the highest-complexity category after considerable feedback from the American Academy of Sleep Medicine.2 This change suggests that they more fully recognize the clinical judgment and expertise involved in interpreting more complex studies.
At iSleep Physicians, we believe physician interpretation remains fundamental to diagnostic quality and patient safety. Technology can improve efficiency and support clinical decision-making, but it cannot replace the medical judgment necessary to translate diagnostic information into appropriate patient care. As reimbursement models evolve, preserving the value of physician expertise must remain a priority.
Protecting Patient Access and the Future of Sleep Medicine
Beyond the financial and administrative implications, the potential impact of these changes on patient access deserves serious attention. HST has expanded access to diagnostic services by allowing appropriately selected patients to complete testing outside traditional sleep laboratories. Medicare coverage policies recognize HST as an option for diagnosing OSA when applicable clinical and coverage requirements are satisfied.3 For patients in rural or underserved communities, home testing may help overcome geographic and logistical barriers that would otherwise delay diagnosis and treatment.
If reimbursement becomes insufficient to support high-quality testing programs, some organizations may reconsider their participation in certain markets. This could reduce diagnostic availability, increase wait times, and create additional challenges for patients who already face limited access to sleep medicine specialists. Modernization should not inadvertently undermine the accessibility that has made HST such an important advancement in our field.
The January 2027 transition presents both challenges and opportunities for the sleep medicine community. A more sophisticated coding framework has the potential to better recognize differences in diagnostic technology and clinical complexity, but successful implementation will depend on whether reimbursement accurately reflects the resources, expertise, and infrastructure required to deliver high-quality care.
For providers, the coming months represent an opportunity to evaluate financial models, strengthen operational processes, improve documentation, and engage with industry stakeholders. The true impact of these changes will become clearer throughout 2027 as organizations begin submitting claims under the new framework and evaluating reimbursement outcomes.
Ultimately, the success of this transition should not be measured solely by new CPT codes or payment calculations. It should be measured by whether sleep medicine providers can continue delivering accurate, accessible, and clinically meaningful diagnostic services. As an industry, our responsibility is to ensure that reimbursement modernization supports innovation while preserving the quality of care our patients depend on.

Fatima Denney is chief operational officer and executive vice president of iSleep Physicians, which offers specialized sleep consultations and comprehensive sleep testing interpretations with personalized care across all 50 states in the U.S.
References
- Centers for Medicare & Medicaid Services. Calendar year (CY) 2027 Medicare physician fee schedule proposed rule. Published July 14, 2026. Accessed October 16, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule.
- American Academy of Sleep Medicine. CMS finalizes payment values for new unattended sleep testing codes. Published November 6, 2026. Accessed November 8, 2026. https://aasm.org/cms-finalizes-payment-values-for-new-unattended-sleep-testing-codes.
- Centers for Medicare & Medicaid Services. Medicare and Medicaid programs; CY 2027 payment policies under the physician fee schedule and other changes to Part B payment and coverage policies; Medicare Shared Savings Program requirements; and Medicare Prescription Drug Inflation Rebate Program. Proposed rule. (CMS-1848-P). Federal Register. 2026;91(135):43842-44557. https://www.federalregister.gov/d/2026-14327.
- Centers for Medicare & Medicaid Services. Polysomnography and other sleep studies. Local Coverage Determination L3861. Revised September 11, 2025. Accessed October 16, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36861.








